Total expenditure increased by 30% YoY to Rs 372.05 crore during the quarter, due to higher raw material costs (up 23% YoY), higher selling and distribution expenses (up 162% YoY), higher power and fuel charges (up 44% YoY) and higher travelling expenses (up 38% YoY).
Profit before tax in Q3 FY22 stood at Rs 27.13 crore, up by 14% from Rs 23.80 crore reported in Q3 FY21. The company recorded a current tax outgo of Rs 5.61 crore during the period under review.
Morepen Laboratories is a pharmaceutical and healthcare products company. It is a leading manufacturer of high-quality APIs, home diagnostics, formulations and OTC products in north India.
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
